tradingkey.logo

FDA Investigates Death Linked to Adzynma Treatment for Congenital Thrombotic Thrombocytopenic Purpura

ReutersNov 21, 2025 4:50 PM

- FDA:

  • FDA INVESTIGATING DEATH DUE TO NEUTRALIZING ANTIBODIES TO ADAMTS13 FOLLOWING ADZYNMA TREATMENT OF CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI